NCT06360289View on ClinicalTrials.gov

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Hereditary Amyloidosis, Transthyretin-RelatedAsymptomatic Carrier State
Interventions
OTHER

Standard of Care

This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.

Trial Locations (1)

94270

RECRUITING

Centre Hospitalier Universitaire (CHU) Le Kremlin-Bicêtre Assistance Publique-Hôpitaux de Paris (APHP), Paris

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY